University’s cutting-edge Digital Health Enterprize Zone will host trials. The world’s first Covid-19 vaccine booster vaccine is to be administered at the University of Bradford’s cutting-edge Digital Health Enterprise Zone on June 1. The jabs are being tested as a possible precaution against variants of the coronavirus, with the initial trial lasting one year.
A total of 148 people will receive doses over several days, a quarter of those being placebos – patients will then return to the centre after 28 days and then be monitored at regular intervals.
Volunteers are still needed – anyone aged 30-69 or 69 and over and has had two doses of either the Astrazeneca vaccine (AZ) or Pfizer vaccine who wants to volunteer can log onto www.covboost.org to find out more.
The trial is being conducted by Bradford Teaching Hospitals NHS Foundation Trust in partnership with the University, as part of a £90m trial sanctioned by the Department of Health & Social Care. The trials will be conducted at 18 sites across the UK and will involve 3,000 people – 148 of those will be treated in Bradford. Volunteers will be aged split into two groups: 30-69 and 69 and over, all of whom have already had TWO JABS of either AZ or Pfeizer.
Health experts from across the world will be watching the outcome of the trials to see whether booster jabs increase the efficacy of vaccines.
Honorary Visiting Professor Dinesh Saralaya is a Respiratory Physician at Bradford Teaching Hospitals NHS Foundation Trust (BTHFT) and director of the National Institute for Health Research (NIHR) patient recruitment centre in Bradford.
He said: “This is a significant moment for Bradford, both for the University and the hospital and it shows once again how strong that partnership is. These trials will provide valuable information which could help save lives in the fight against Covid-19.”
Dr Liz Breen is director of the Digital Health Enterprise Zone, which also hosted the Novavax vaccine trials. She said: “We’re honoured to be hosting the next wave of trials, which are the booster trials. Having this happen within a facility that’s Bradford-based will give more confidence to the community and it will build on the success of the vaccine rollout.”
Source: University of Bradford